NASDAQ:OCX - Nasdaq - US68235C2061 - Common Stock - Currency: USD
NASDAQ:OCX (2/21/2025, 8:00:01 PM)
2.65
-0.07 (-2.57%)
The current stock price of OCX is 2.65 USD. In the past month the price increased by 31.84%. In the past year, price decreased by -13.54%.
Symbol | Name | TA | FA | PE | Market Cap |
---|---|---|---|---|---|
ABBV | ABBVIE INC | 19.97 | 357.10B | ||
AMGN | AMGEN INC | 15.29 | 162.72B | ||
GILD | GILEAD SCIENCES INC | 23.85 | 137.00B | ||
VRTX | VERTEX PHARMACEUTICALS INC | 1669.79 | 124.40B | ||
REGN | REGENERON PHARMACEUTICALS | 15.34 | 76.56B | ||
ARGX | ARGENX SE - ADR | N/A | 39.16B | ||
ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 32.32B | ||
BNTX | BIONTECH SE-ADR | N/A | 28.77B | ||
ONC | BEIGENE LTD-ADR | N/A | 27.25B | ||
NTRA | NATERA INC | N/A | 21.43B | ||
BIIB | BIOGEN INC | 8.54 | 20.49B | ||
SMMT | SUMMIT THERAPEUTICS INC | N/A | 16.31B |
OncoCyte Corp. is a molecular diagnostics company, which engages in the development and commercialization of diagnostic tests for the detection of cancer, including molecular diagnostic services to pharmaceutical customers. The company is headquartered in Irvine, California and currently employs 43 full-time employees. The company went IPO on 2015-12-30. The firm is engaged in the development of Oncocytes tests and the acquisition of proprietary molecular technologies in the fields of oncology and transplantation. The Company’s products include DetermaIO, VitaGraft, DetermaCNI and GraftAssure. DetermaIO is a gene expression test that assesses the tumor microenvironment to predict response to immunotherapies. DetermaIO measures the expression level of 27 selected genes, which are interpreted through the use of a proprietary algorithm (patent pending) which computes a quantitative score (IO Score) that incorporates information from the immune inflammatory infiltrates within and around the tumor. Its pipeline test, DetermaCNI, is a blood-based monitoring tool for monitoring therapeutic efficacy in cancer patients. VitaGraft is a blood-based solid organ transplantation monitoring test. GraftAssure is a research use only blood-based solid organ transplantation monitoring test.
ONCOCYTE CORP
15 Cushing
Irvine CALIFORNIA 92618 US
CEO: Ronald Andrews
Employees: 43
Company Website: https://oncocyte.com/
Investor Relations: https://investors.oncocyte.com/
Phone: 19494097600
The current stock price of OCX is 2.65 USD. The price decreased by -2.57% in the last trading session.
The exchange symbol of ONCOCYTE CORP is OCX and it is listed on the Nasdaq exchange.
OCX stock is listed on the Nasdaq exchange.
7 analysts have analysed OCX and the average price target is 4.21 USD. This implies a price increase of 58.77% is expected in the next year compared to the current price of 2.65. Check the ONCOCYTE CORP stock analysts ratings, price target forecast and up-and down grades for more detailed information.
ONCOCYTE CORP (OCX) has a market capitalization of 55.81M USD. This makes OCX a Micro Cap stock.
ONCOCYTE CORP (OCX) currently has 43 employees.
ONCOCYTE CORP (OCX) has a resistance level at 2.77. Check the full technical report for a detailed analysis of OCX support and resistance levels.
The Revenue of ONCOCYTE CORP (OCX) is expected to decline by -66.95% in the next year. Check the estimates tab for more information on the OCX EPS, Sales, EBIT and EBITDA future analyst estimates.
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
OCX does not pay a dividend.
ONCOCYTE CORP (OCX) will report earnings on 2025-04-10, after the market close.
ONCOCYTE CORP (OCX) does not have a PE ratio as the earnings reported over the last twelve months were negative (-4.59).
The outstanding short interest for ONCOCYTE CORP (OCX) is 1.97% of its float. Check the ownership tab for more information on the OCX short interest.
ChartMill assigns a technical rating of 5 / 10 to OCX. When comparing the yearly performance of all stocks, OCX is a bad performer in the overall market: 74.93% of all stocks are doing better.
ChartMill assigns a fundamental rating of 1 / 10 to OCX. Both the profitability and financial health of OCX have multiple concerns.
Over the last trailing twelve months OCX reported a non-GAAP Earnings per Share(EPS) of -4.59. The EPS increased by 51.58% compared to the year before.
Industry Rank | Sector Rank | ||
---|---|---|---|
PM (TTM) | N/A | ||
ROA | -62.11% | ||
ROE | -449.08% | ||
Debt/Equity | 0.07 |
ChartMill assigns a Buy % Consensus number of 74% to OCX. The Buy consensus is the average rating of analysts ratings from 7 analysts.
For the next year, analysts expect an EPS growth of 20.01% and a revenue growth -66.95% for OCX